Fifth Third Bancorp
MDGL icon

Fifth Third Bancorp’s Madrigal Pharmaceuticals MDGL Stock Holding History

Fifth Third Bancorp’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Sell
810
-22
-3% -$11.3K ﹤0.01% 2177
2026
Q1 		$435K Buy
+832
New +$397K ﹤0.01% 2111
2025
Q2 		– Sell
-1
Closed -$331 – 2611
2025
Q1 		$331 Buy
+1
New +$329 ﹤0.01% 2469

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fifth Third Bancorp's MDGL Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Madrigal Pharmaceuticals (MDGL) stake by 2.6% in Q2 2026, selling an estimated $11.3K and leaving 810 shares worth $435K. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

Fifth Third Bancorp first reported a position in MDGL in Q1 2025 and has held it in 3 quarters since. The position peaked at $435K in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Fifth Third Bancorp held 810 shares of Madrigal Pharmaceuticals worth $435K as of Q2 2026.
  • Fifth Third Bancorp sold 22 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $11.3K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #2177 holding.
  • Fifth Third Bancorp first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Fifth Third Bancorp's Madrigal Pharmaceuticals position peaked at $435K in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.